Multiple high-impact breakthroughs demonstrate artificial intelligence’s growing role in biopharma innovation. The Arc Institute’s Germinal platform couples AlphaFold-Multimer structural predictions with antibody language modeling to markedly improve epitope-targeted antibody design, reducing wet-lab screening demands. Additionally, CRISPR-based genetic screening by scientists at Mass General Brigham and the Broad Institute identify gene knockouts that enhance CAR T cell therapy efficacy against multiple myeloma. These advances position AI and gene editing as transformative tools for accelerating precision drug development and immunotherapies.